메뉴 건너뛰기




Volumn 122, Issue 14, 2013, Pages 2331-2337

PANORAMA 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; PANOBINOSTAT; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; HYDROXAMIC ACID; INDOLE DERIVATIVE; PYRAZINE DERIVATIVE;

EID: 84884699420     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-481325     Document Type: Article
Times cited : (257)

References (25)
  • 1
    • 33644831033 scopus 로고    scopus 로고
    • Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group
    • Eastern Cooperative Oncology Group
    • Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24(3):431-436.
    • (2006) J Clin Oncol , vol.24 , Issue.3 , pp. 431-436
    • Rajkumar, S.V.1    Blood, E.2    Vesole, D.3    Fonseca, R.4    Greipp, P.R.5
  • 2
    • 0036843032 scopus 로고    scopus 로고
    • Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
    • Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20(21):4319-4323.
    • (2002) J Clin Oncol , vol.20 , Issue.21 , pp. 4319-4323
    • Rajkumar, S.V.1    Hayman, S.2    Gertz, M.A.3
  • 3
    • 84860907057 scopus 로고    scopus 로고
    • Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
    • Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375-4382.
    • (2012) Blood , vol.119 , Issue.19 , pp. 4375-4382
    • Kumar, S.1    Flinn, I.2    Richardson, P.G.3
  • 4
    • 77954618168 scopus 로고    scopus 로고
    • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    • Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5): 679-686.
    • (2010) Blood , vol.116 , Issue.5 , pp. 679-686
    • Richardson, P.G.1    Weller, E.2    Lonial, S.3
  • 5
    • 0345447210 scopus 로고    scopus 로고
    • Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
    • Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508-513.
    • (2003) Oncologist , vol.8 , Issue.6 , pp. 508-513
    • Kane, R.C.1    Bross, P.F.2    Farrell, A.T.3    Pazdur, R.4
  • 6
    • 0037973279 scopus 로고    scopus 로고
    • A phase 2 study of bortezomib in relapsed, refractory myeloma
    • Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 2609-2617.
    • (2003) N Engl J Med , vol.348 , Issue.26 , pp. 2609-2617
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 7
    • 36349023319 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    • Multiple Myeloma (010) Study Investigators
    • Dimopoulos M, Spencer A, Attal M, et al Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21): 2123-2132.
    • (2007) N Engl J Med , vol.357 , Issue.21 , pp. 2123-2132
    • Dimopoulos, M.1    Spencer, A.2    Attal, M.3
  • 8
    • 36349010285 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    • Multiple Myeloma (009) Study Investigators
    • Weber DM, Chen C, Niesvizky R, et al Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21):2133-2142.
    • (2007) N Engl J Med , vol.357 , Issue.21 , pp. 2133-2142
    • Weber, D.M.1    Chen, C.2    Niesvizky, R.3
  • 9
    • 84856719479 scopus 로고    scopus 로고
    • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
    • International Myeloma Working Group
    • Kumar SK, Lee JH, Lahuerta JJ, et al International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157.
    • (2012) Leukemia , vol.26 , Issue.1 , pp. 149-157
    • Kumar, S.K.1    Lee, J.H.2    Lahuerta, J.J.3
  • 10
    • 67349228774 scopus 로고    scopus 로고
    • Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
    • Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280(2):233-241.
    • (2009) Cancer Lett , vol.280 , Issue.2 , pp. 233-241
    • Atadja, P.1
  • 11
    • 33751172982 scopus 로고    scopus 로고
    • Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
    • Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108(10):3441-3449.
    • (2006) Blood , vol.108 , Issue.10 , pp. 3441-3449
    • Catley, L.1    Weisberg, E.2    Kiziltepe, T.3
  • 12
    • 83455251274 scopus 로고    scopus 로고
    • A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma
    • San-Miguel JF, Richardson PGG, Sezer O, et al. A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2011;29(15-suppl):8075.
    • (2011) J Clin Oncol , vol.29 , Issue.15 SUPPL. , pp. 8075
    • San-Miguel, J.F.1    Richardson, P.G.G.2    Sezer, O.3
  • 13
    • 18244428600 scopus 로고    scopus 로고
    • European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation
    • Myeloma Subcommittee of the EBMT
    • Bladé J, Samson D, Reece D, et al Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-1123.
    • (1998) Br J Haematol , vol.102 , Issue.5 , pp. 1115-1123
    • Bladé, J.1    Samson, D.2    Reece, D.3
  • 14
    • 84988241358 scopus 로고    scopus 로고
    • International uniform response criteria for multiple myeloma
    • International Myeloma Working Group
    • Durie BG, Harousseau JL, Miguel JS, et al International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
    • (2006) Leukemia , vol.20 , Issue.9 , pp. 1467-1473
    • Durie, B.G.1    Harousseau, J.L.2    Miguel, J.S.3
  • 15
    • 79955977910 scopus 로고    scopus 로고
    • Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1
    • International Myeloma Workshop Consensus Panel 1
    • Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.
    • (2011) Blood , vol.117 , Issue.18 , pp. 4691-4695
    • Rajkumar, S.V.1    Harousseau, J.L.2    Durie, B.3
  • 16
    • 0038509089 scopus 로고    scopus 로고
    • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group
    • International Myeloma Working Group
    • International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
    • (2003) Br J Haematol , vol.121 , Issue.5 , pp. 749-757
  • 17
    • 79751534825 scopus 로고    scopus 로고
    • Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes
    • Giver CR, Jaye DL, Waller EK, Kaufman JL, Lonial S. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia. 2011;25(2):362-365.
    • (2011) Leukemia , vol.25 , Issue.2 , pp. 362-365
    • Giver, C.R.1    Jaye, D.L.2    Waller, E.K.3    Kaufman, J.L.4    Lonial, S.5
  • 18
    • 79953725710 scopus 로고    scopus 로고
    • Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitorinduced thrombocytopenia
    • Bishton MJ, Harrison SJ, Martin BP, et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitorinduced thrombocytopenia. Blood. 2011;117(13):3658-3668.
    • (2011) Blood , vol.117 , Issue.13 , pp. 3658-3668
    • Bishton, M.J.1    Harrison, S.J.2    Martin, B.P.3
  • 19
    • 84862511317 scopus 로고    scopus 로고
    • Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation
    • Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol. 2012;40(7):564-574.
    • (2012) Exp Hematol , vol.40 , Issue.7 , pp. 564-574
    • Iancu-Rubin, C.1    Gajzer, D.2    Mosoyan, G.3    Feller, F.4    Mascarenhas, J.5    Hoffman, R.6
  • 20
    • 84861804180 scopus 로고    scopus 로고
    • Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: Final study results of a global phase 2b trial
    • ASH Annual Meeting Abstracts Abstract 480
    • Siegel DS, Dimopoulos MA, Yoon S, et al. Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial [ASH Annual Meeting Abstracts]. Blood. 2011;118(21). Abstract 480.
    • (2011) Blood , vol.118 , Issue.21
    • Siegel, D.S.1    Dimopoulos, M.A.2    Yoon, S.3
  • 21
    • 84877622448 scopus 로고    scopus 로고
    • Pomalidomide plus lowdose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
    • Intergroupe Francophone du Myélome
    • Leleu X, Attal M, Arnulf B, et al Intergroupe Francophone du Myélome. Pomalidomide plus lowdose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121(11):1968- 1975.
    • (2013) Blood , vol.121 , Issue.11 , pp. 1968-1975
    • Leleu, X.1    Attal, M.2    Arnulf, B.3
  • 22
    • 84884702467 scopus 로고    scopus 로고
    • Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT)
    • Vij R, Richardson PGG, Jagannath S, et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). J Clin Oncol. 2012; 30(15-suppl):8016.
    • (2012) J Clin Oncol , vol.30 , Issue.15 SUPPL. , pp. 8016
    • Vij, R.1    Richardson, P.G.G.2    Jagannath, S.3
  • 23
    • 84880091523 scopus 로고    scopus 로고
    • Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma
    • ASH Annual Meeting Abstracts Abstract 947
    • Lendvai N, Landau H, Lesokhin A, et al. Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma [ASH Annual Meeting Abstracts]. Blood. 2012;120(21). Abstract 947.
    • (2012) Blood , vol.120 , Issue.21
    • Lendvai, N.1    Landau, H.2    Lesokhin, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.